TG Therapeutics Inc (TGTX)

10.85
NASDAQ : Health Care
Prev Close 11.00
Day Low/High 10.73 / 11.05
52 Wk Low/High 4.10 / 15.35
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 68.84M
Market Cap 757.19M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2017 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2017 Financial Results And Business Update

Investor Conference Call to be held Wednesday, August 9, 2017 at 8:30am ET

Interesting TGTX Put And Call Options For September 15th

Investors in TG Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

Short Interest In TG Therapeutics Moves 16.6% Higher

Short Interest In TG Therapeutics Moves 16.6% Higher

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 2,433,158 share increase in total short interest for TG Therapeutics Inc , to 17,111,572, an increase of 16.58% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Lockheed Martin, TG Therapeutics, HD Supply: 'Mad Money' Lightning Round

Lockheed Martin, TG Therapeutics, HD Supply: 'Mad Money' Lightning Round

Jim Cramer is bullish on Lockheed Martin, TG Therapeutics, and HD Supply.

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Growth is crushing value, says Jim Cramer, and the dynamic is more pronounced in individual sectors.

Smart Money Is Active in General Electric, Home Depot and More

Smart Money Is Active in General Electric, Home Depot and More

Smart money footprints are here!

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 14th International Conference On Malignant Lymphoma

Three abstracts have been selected for oral presentation, including the positive results from the GENUINE Phase 3 study, and one for poster presentation

TG Therapeutics, Inc. To Present At The 2017 Jefferies Global Healthcare Conference

Presentation Scheduled for Thursday, June 8, 2017 at 2:00pm ET

TG Therapeutics, Inc. Recaps Schedule Of Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The American Society Of Clinical Oncology

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

5 Stocks Setting Up for Big Breakouts

5 Stocks Setting Up for Big Breakouts

Here's how to potentially rake in some fat profits off a number of hot breakout setups.

The Machines Are Sapping the Fun out of This Day

The Machines Are Sapping the Fun out of This Day

Historically, the day before a holiday often has a positive bias, but the algos have killed emotion.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL

TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL

The analysis was conducted by the Data and Safety Monitoring Board (DSMB) which found no safety concerns and recommended continuation of enrollment without modification in a trial.

Shark Bites: There Wasn't Even a Dip to Buy

Shark Bites: There Wasn't Even a Dip to Buy

Action runs counter to pattern, leaving market players wondering what to do.

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 14th International Conference On Malignant Lymphoma

Three abstracts have been selected for oral presentation, including the positive results from the GENUINE Phase 3 study, and one for poster presentation

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 22nd European Hematology Association Annual Congress

Presentations highlight triple combination therapies with the combination of TG-1101 and TGR-1202 as the backbone

TG Therapeutics, Inc. Recaps Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The American Society Of Clinical Oncology

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation